A Canadian Registry of Folfirinox in Advanced/Metastatic Pancreatic Cancer

Background: Clinical trial results are usually not validated once a regimen is introduced in clinical practice. The efficacy, tolerability, and quality of life of FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) were demonstrated in the ACCORD clinical trial (Conroy et al, NEJM 2011). Concerns were related to safety, particularly neutropenic sepsis. Knowledge about oncologists’ implementation approach of this regimen, and clinical management and outcomes of patients receiving FOLFIRINOX combination in clinical practice could help improve on treatment delivery options. Methods: Members of the Canadian Association of Medical Oncologists were invited to participate in a registry to collect information on the treatment and clinical course of patients with advanced/metastatic pancreatic cancer treated with FOLFIRINOX in a regular clinical setting. Data for the planned 200 registry patients is collected via a commissioned web-based collection system. The registry covers all consecutive